학술논문
Nanoparticle-Delivered HIV Peptides to Dendritic Cells a Promising Approach to Generate a Therapeutic Vaccine.
Document Type
Academic Journal
Author
Martín-Moreno A; Section of Immunology, ImmunoBiology Molecular Laboratory, Spanish HIV HGM BioBank, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain.; Jiménez Blanco JL; Department of. Química Orgánica, Facultad de Química, Universidad de Sevilla, 41012 Sevilla, Spain.; Mosher J; Department of Chemistry & Biochemistry, Central Michigan University, Mount Pleasant, MI 48859, USA.; Swanson DR; Department of Chemistry & Biochemistry, Central Michigan University, Mount Pleasant, MI 48859, USA.; García Fernández JM; Institute for Chemical Research, CSIC-University of Sevilla, 41092 Sevilla, Spain.; Sharma A; Department of Chemistry & Biochemistry, Central Michigan University, Mount Pleasant, MI 48859, USA.; Ceña V; CIBERNED, Instituto de Salud Carlos III, 28031 Madrid, Spain.; Unidad Asociada Neurodeath, Facultad de Medicina, Universidad de Castilla-La Mancha, 02006 Albacete, Spain.; Muñoz-Fernández MA; Section of Immunology, ImmunoBiology Molecular Laboratory, Spanish HIV HGM BioBank, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain.; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, 28034 Madrid, Spain.
Source
Publisher: MDPI Country of Publication: Switzerland NLM ID: 101534003 Publication Model: Electronic Cited Medium: Print ISSN: 1999-4923 (Print) Linking ISSN: 19994923 NLM ISO Abbreviation: Pharmaceutics Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
1999-4923
Abstract
Finding a functional cure for HIV-1 infection will markedly decrease the social and economic burden of this disease. In this work, we have taken advantage of the antigen presenting cell role of human dendritic cells (DCs) to try to induce an immune response to HIV-derived peptide delivered to DCs using two different polycationic nanoparticles: a G4 PAMAM dendrimer modified to a 70/30 ratio of hydroxyl groups/amines and a cyclodextrin derivative. We have studied peptide delivery using a fluorescence peptide and have studied the immune response generation by cytokine determination and flow cytometry. We have found a robust delivery of the antigenic peptide to DCs and activated dendritic cell-mediated peripheral blood mononuclear cells (PBMCs) proliferation using the mixed lymphocyte reaction. However, no expression of markers indicating activation of either B or T lymphocytes was observed. Moreover, the release of the pro-inflammatory cytokine TNF-α or IL-2 was only observed when DCs treated with either the dendrimer or the dendriplex containing the peptide. Antigenic peptide delivery to DCs is a promising approach to generate a vaccine against HIV-1 infection. However, more studies, including the simultaneous delivery of several antigenic peptides from different viral proteins, can markedly improve the immune response.
Competing Interests: The authors declare no conflict of interest.
Competing Interests: The authors declare no conflict of interest.